{
    "clinical_study": {
        "@rank": "107588", 
        "arm_group": [
            {
                "arm_group_label": "LX4211", 
                "arm_group_type": "Experimental", 
                "description": "400 mg of LX4211"
            }, 
            {
                "arm_group_label": "Canagliflozin", 
                "arm_group_type": "Active Comparator", 
                "description": "300 mg canagliflozin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "LX4211 placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of LX4211 and the comparator drug\n      canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy\n      subjects in comparison to placebo."
        }, 
        "brief_title": "Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects", 
        "condition": "Healthy Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects \u226518 to \u226455 years of age\n\n          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140\n             mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm\n\n          -  Body mass index (BMI) \u226518 and \u226435 kg/sq m\n\n          -  Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)\n             within 7 days of dosing\n\n          -  Use of any investigational agent or study treatment within 30 days of Day -1\n\n          -  Use of any protein or antibody-based therapeutic agents within 3 months of Screening\n\n          -  Prior exposure to LX4211 or canagliflozin\n\n          -  Daily use of >5 cigarettes or any tobacco products within 6 weeks prior to Screening\n             and while participating in the study\n\n          -  History of bariatric surgery or any other gastrointestinal surgery that may induce\n             malabsorption\n\n          -  History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI\n             procedure for the purpose of weight loss which would slow gastric emptying\n\n          -  History of any major surgery within 6 months prior to Screening\n\n          -  History of any hypersensitivity to the inactive components of LX4211, inactive\n             components of canagliflozin, acetaminophen oral solution or any inactive component of\n             acetaminophen liquid preparation\n\n          -  History of renal disease or significantly abnormal kidney function tests\n\n          -  History of hepatic disease or significantly abnormal liver function tests\n\n          -  History of any active infection within 30 days prior to Day -1\n\n          -  History of alcohol or substance abuse within 2 years prior to Day 1\n\n          -  History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1\n             or HIV-2\n\n          -  Donation or loss of >500 mL of blood or blood product within 56 days of Day -1\n\n          -  positive pregnancy test at Screening or Day -1\n\n          -  Positive urine screen for drugs of abuse at Screening or Day -1\n\n          -  Positive breath test for alcohol at Screening or Day -1\n\n          -  Inability or difficulty swallowing whole tablets\n\n          -  Unable or unwilling to communicate or cooperate with the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916863", 
            "org_study_id": "LX4211.1-111-NRM", 
            "secondary_id": "LX4211.111"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LX4211", 
                    "Canagliflozin", 
                    "Placebo"
                ], 
                "intervention_name": "LX4211 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LX4211", 
                    "Canagliflozin", 
                    "Placebo"
                ], 
                "intervention_name": "canagliflozin 300 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LX4211", 
                    "Canagliflozin", 
                    "Placebo"
                ], 
                "intervention_name": "LX4211 Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chula Vista", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91911"
                }, 
                "name": "Lexicon Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA\u2122 (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods", 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Paul Strumph, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in rate of glucose appearance after meal (RaO)", 
            "safety_issue": "No", 
            "time_frame": "Days 1, 8, 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916863"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of total glucose appearance (RaT)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 8, 15"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 8, 15"
            }, 
            {
                "measure": "Change from baseline in postprandial glucose", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 8, 15"
            }, 
            {
                "measure": "Change from baseline in insulin", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 8, 15"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}